Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Dalteparin sodium
Pfizer Ltd
B01AB04
Dalteparin sodium
25000unit/1ml
Solution for injection
Subcutaneous
No Controlled Drug Status
Valid as a prescribable product
BNF: 02080100; GTIN: 5012882008123
Page 1 of 9 PACKAGE LEAFLET: INFORMATION FOR THE USER FRAGMIN® 2,500 IU/0.2 ML & 5,000 IU/0.2 ML SOLUTION FOR INJECTION dalteparin sodium READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. If your doctor has given you this medicine to use at home do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Fragmin is and what it is used for 2. What you need to know before you are given or use Fragmin 3. How Fragmin is given to you 4. Possible side effects 5. How to store Fragmin 6. Contents of the pack and other information 1. WHAT FRAGMIN IS AND WHAT IT IS USED FOR Fragmin is a solution for injection. Its active ingredient is dalteparin sodium. Fragmin belongs to a group of medicines called low molecular weight heparins or antithrombotics, which help prevent the formation of blood clots by thinning the blood. Venous thromboembolism is a condition where blood clots develop in the legs (deep vein thrombosis) or the lungs (pulmonary embolism), e.g. after surgery, prolonged bed rest or in patients with certain types of cancer. • Fragmin is used to prevent blood clots (venous thromboembolism) forming before and after an operation or if you are bedridden due to illness and to prevent their recurrence. The 5000 IU product can also be used for: • Prevention of deep vein thrombosis in patients bedridden due to a medical condition but not limited to, for example heart failure and respiratory failure. • Treatment of patients with solid tumours who suffer from low platelet counts. Ask your doctor if you are unsure why you have been given Fra Read the complete document
OBJECT 1 FRAGMIN 5000 IU Summary of Product Characteristics Updated 19-May-2016 | Pfizer Limited 1. Name of the medicinal product Fragmin ® 5000 IU 2. Qualitative and quantitative composition Active ingredient Dalteparin sodium (INN) Quality according to Ph.Eur. and in-house specification. Potency is described in International anti-Factor Xa units (IU) of the 1st International Standard for Low Molecular Weight Heparin. Content of active ingredient Fragmin 5000 IU: single dose syringe containing dalteparin sodium 5000 IU (anti-Factor Xa) in 0.2 ml solution. Fragmin syringes do not contain preservatives. 3. Pharmaceutical form Solution for injection for subcutaneous administration. 4. Clinical particulars 4.1 Therapeutic indications Peri- and post-operative surgical thromboprophylaxis. The prophylaxis of proximal deep venous thrombosis in patients bedridden due to a medical condition, including, but not limited to; congestive cardiac failure (NYHA class III or IV), acute respiratory failure or acute infection, who also have a predisposing risk factor for venous thromboembolism such as age over 75 years, obesity, cancer or previous history of VTE. Patients with solid tumours: Extended treatment of symptomatic venous thromboembolism (VTE) and prevention of its recurrence. 4.2 Posology and method of administration PERI- AND POST-OPERATIVE SURGICAL THROMBOPROPHYLAXIS: ADULTS Surgical thromboprophylaxis in patients at high risk of thrombosis: 2,500 IU is administered subcutaneously 1-2 hours before the surgical procedure and 2,500 IU subcutaneously 8-12 hours later. On the following days, 5,000 IU subcutaneously each morning. As an alternative, 5,000 IU is administered subcutaneously the evening before the surgical procedure and 5,000 IU subcutaneously the following evenings. Treatment is continued until the patient is mobilised, in general 5-7 days or longer. Prolonged thromboprophylaxis in hip replacement surgery: 5,000IU is given subcutaneously the evening before the operation and 5,000IU subcutaneously the followin Read the complete document